Income statement
USD
Annual
| Metric | 2025 | 2024 | 2020 |
|---|---|---|---|
| Revenue | 428M | 305M | 0 |
| Gross Profit | 298M | 194M | 0 |
| Operating Income | -13M | -23M | -206K |
| EBITDA | 25M | -23M | -192K |
| Net Income | -21M | -52M | -192K |
| EPS (Diluted) | — | — | — |
Financial Services
Live Price
Offline$13.00
-4.55% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CM Life Sciences, Inc. (CMLFU) is a Financial Services stock with a market cap of $10.31B. The stock last traded around $13.00. Baseline metrics include revenue growth of +40.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +62.4%, free cash flow +142.0% with operating margin -14.9% and ROIC -15.5%. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CMLFU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CMLFU
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CMLFU Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CMLFU and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$192.0K
+99.6% YoY
Free Cash Flow
-$34.0M
-338.3% YoY
Revenue Growth
+40.0%
EPS Growth
+62.4%
Gross Margin
69.6%
Net Margin
-17.6%
Income statement
USD
| Metric | 2025 | 2024 | 2020 |
|---|---|---|---|
| Revenue | 428M | 305M | 0 |
| Gross Profit | 298M | 194M | 0 |
| Operating Income | -13M | -23M | -206K |
| EBITDA | 25M | -23M | -192K |
| Net Income | -21M | -52M | -192K |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2020 |
|---|---|---|---|
| Cash & Equivalents | 105M | 85M | 1M |
| Total Assets | 524M | 419M | 444M |
| Total Liabilities | 216M | 174M | 16M |
| Shareholder Equity | 308M | 245M | 429M |
| Total Debt | 60M | 64M | 0 |
| Net Debt | -45M | -21M | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
-185.6% YoY
Capital Expenditures
5M
+71.1% YoY
Free Cash Flow
34M
-338.3% YoY
Key ratios
Gross Margin
69.6%
Operating Margin
-14.9%
Net Margin
-17.6%
ROE
-27.5%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.